Inhibition of the mechanistic target of rapamycin (mTOR) pathway by rapamycin (RAPA), an
FDA-approved immunosuppressive drug used as a clinical therapy to prevent solid organ …

Inhibition of the mTOR (mechanistic target of rapamycin) signaling pathway by the FDA-
approved drug rapamycin promotes life span in numerous model organisms and delays age …

In 2009, rapamycin was reported to increase the lifespan of mice when implemented later in
life. This observation resulted in a sea-change in how researchers viewed aging. This was …

Aging is a major risk factor for a large number of disorders and functional impairments.
Therapeutic targeting of the aging process may therefore represent an innovative strategy in …

This report is the first description of dosing procedures, pharmacokinetics, biochemical
action, and general tolerability of the antiaging drug rapamycin in the common marmoset, a …

Aging can not only shorten a healthy lifespan, but can also lead to multi-organ dysfunction
and failure. Anti-aging is a complex and worldwide conundrum for eliminating the various …

Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest
experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many …

The drug rapamycin is the only pharmacological agent thus far shown to reproducibly
extend lifespan and delay a subset of age-associated pathologies in multiple strains of mice …

The federal drug administration (FDA)-approved compound rapamycin was the first
pharmacological agent shown to extend maximal lifespan in both genders in a mammalian …

Target of rapamycin inhibition by rapamycin feeding has previously been shown to extend
life in genetically heterogeneous mice. To examine whether it similarly affected mouse …